Sorrento Therapeutics, Inc. (STI) provides access to its novel and proprietary technology platform for the construction of fully human antibody libraries, the STI Technology.

The STI Technology applies RNA transcription for the amplification of human immunoglobin variable domain sequences.

STI was formed in 2006 in San Diego, California. In September 2009,  STI and Quikbyte Software, Inc., a publicly traded shell company, merged and adopted STI’s name.